Does the media favor MBX or ACRS?

In the previous week, MBX Biosciences had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 10 mentions for MBX Biosciences and 8 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.26 beat MBX Biosciences' score of 0.07 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor ACRS or QURE?

In the previous week, Aclaris Therapeutics had 3 more articles in the media than uniQure. MarketBeat recorded 8 mentions for Aclaris Therapeutics and 5 mentions for uniQure. uniQure's average media sentiment score of 0.57 beat Aclaris Therapeutics' score of 0.26 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral uniQure 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ACRS or GRAL more profitable?

GRAIL has a net margin of -236.95% compared to Aclaris Therapeutics' net margin of -921.50%. GRAIL's return on equity of -15.88% beat Aclaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aclaris Therapeutics -921.50% -61.65% -42.41% GRAIL -236.95% -15.88% -14.02%

Does the media refer more to ACRS or GRAL?

In the previous week, GRAIL had 12 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 20 mentions for GRAIL and 8 mentions for Aclaris Therapeutics. GRAIL's average media sentiment score of 0.38 beat Aclaris Therapeutics' score of 0.26 indicating that GRAIL is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral GRAIL 5 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to ACRS or CLDX?

In the previous week, Celldex Therapeutics had 9 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 17 mentions for Celldex Therapeutics and 8 mentions for Aclaris Therapeutics. Celldex Therapeutics' average media sentiment score of 0.69 beat Aclaris Therapeutics' score of 0.26 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Celldex Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACRS or IRON?

In the previous week, Disc Medicine had 15 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 23 mentions for Disc Medicine and 8 mentions for Aclaris Therapeutics. Disc Medicine's average media sentiment score of 0.40 beat Aclaris Therapeutics' score of 0.26 indicating that Disc Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Disc Medicine 8 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aclaris Therapeutics (ACRS) Competitors

$5.91 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$5.82 -0.09 (-1.52%)

As of 08:25 AM Eastern

Compare

ACRS vs. MBX, QURE, GRAL, CLDX, and IRON

Should you buy Aclaris Therapeutics stock or one of its competitors? MarketBeat compares Aclaris Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aclaris Therapeutics include MBX Biosciences (MBX), uniQure (QURE), GRAIL (GRAL), Celldex Therapeutics (CLDX), and Disc Medicine (IRON). These companies are all part of the "biotechnology" industry.

How does Aclaris Therapeutics compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Aclaris Therapeutics (NASDAQ:ACRS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Aclaris Therapeutics has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Aclaris Therapeutics	$7.83M	105.53	-$64.92M	-$0.58	N/A

MBX Biosciences has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

MBX Biosciences currently has a consensus price target of $73.38, indicating a potential upside of 8.19%. Aclaris Therapeutics has a consensus price target of $11.50, indicating a potential upside of 94.59%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

98.3% of Aclaris Therapeutics shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MBX Biosciences has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. MBX Biosciences' return on equity of -26.02% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%

In the previous week, MBX Biosciences had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 10 mentions for MBX Biosciences and 8 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.26 beat MBX Biosciences' score of 0.07 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Aclaris Therapeutics beats MBX Biosciences on 10 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to uniQure?

Aclaris Therapeutics (NASDAQ:ACRS) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aclaris Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, uniQure has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Aclaris Therapeutics currently has a consensus target price of $11.50, indicating a potential upside of 94.59%. uniQure has a consensus target price of $65.00, indicating a potential upside of 40.03%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
uniQure	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Aclaris Therapeutics had 3 more articles in the media than uniQure. MarketBeat recorded 8 mentions for Aclaris Therapeutics and 5 mentions for uniQure. uniQure's average media sentiment score of 0.57 beat Aclaris Therapeutics' score of 0.26 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
uniQure	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclaris Therapeutics has a net margin of -921.50% compared to uniQure's net margin of -1,350.73%. Aclaris Therapeutics' return on equity of -61.65% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
uniQure	-1,350.73%	-111.96%	-29.01%

Aclaris Therapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	105.53	-$64.92M	-$0.58	N/A
uniQure	$16.10M	200.01	-$198.97M	-$4.01	N/A

Summary

Aclaris Therapeutics beats uniQure on 11 of the 17 factors compared between the two stocks.

How does Aclaris Therapeutics compare to GRAIL?

Aclaris Therapeutics (NASDAQ:ACRS) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, GRAIL had 12 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 20 mentions for GRAIL and 8 mentions for Aclaris Therapeutics. GRAIL's average media sentiment score of 0.38 beat Aclaris Therapeutics' score of 0.26 indicating that GRAIL is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
GRAIL	5 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

GRAIL has a net margin of -236.95% compared to Aclaris Therapeutics' net margin of -921.50%. GRAIL's return on equity of -15.88% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
GRAIL	-236.95%	-15.88%	-14.02%

Aclaris Therapeutics has higher earnings, but lower revenue than GRAIL. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	105.53	-$64.92M	-$0.58	N/A
GRAIL	$147.17M	21.09	-$408.35M	-$9.75	N/A

Aclaris Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, GRAIL has a beta of 3.24, meaning that its share price is 224% more volatile than the broader market.

Aclaris Therapeutics currently has a consensus target price of $11.50, indicating a potential upside of 94.59%. GRAIL has a consensus target price of $67.78, indicating a potential downside of 2.45%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aclaris Therapeutics is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

98.3% of Aclaris Therapeutics shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 1.8% of GRAIL shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aclaris Therapeutics and GRAIL tied by winning 8 of the 16 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Celldex Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Celldex Therapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Celldex Therapeutics' return on equity of -52.35% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Celldex Therapeutics	N/A	-52.35%	-47.61%

98.3% of Aclaris Therapeutics shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aclaris Therapeutics has higher revenue and earnings than Celldex Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	105.53	-$64.92M	-$0.58	N/A
Celldex Therapeutics	$1.54M	2,125.86	-$258.76M	-$4.35	N/A

Aclaris Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Aclaris Therapeutics presently has a consensus price target of $11.50, indicating a potential upside of 94.59%. Celldex Therapeutics has a consensus price target of $55.46, indicating a potential upside of 32.97%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aclaris Therapeutics is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Celldex Therapeutics had 9 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 17 mentions for Celldex Therapeutics and 8 mentions for Aclaris Therapeutics. Celldex Therapeutics' average media sentiment score of 0.69 beat Aclaris Therapeutics' score of 0.26 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Celldex Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Celldex Therapeutics beats Aclaris Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Aclaris Therapeutics compare to Disc Medicine?

Aclaris Therapeutics (NASDAQ:ACRS) and Disc Medicine (NASDAQ:IRON) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Aclaris Therapeutics presently has a consensus price target of $11.50, suggesting a potential upside of 94.59%. Disc Medicine has a consensus price target of $106.00, suggesting a potential upside of 36.88%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aclaris Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Aclaris Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.

In the previous week, Disc Medicine had 15 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 23 mentions for Disc Medicine and 8 mentions for Aclaris Therapeutics. Disc Medicine's average media sentiment score of 0.40 beat Aclaris Therapeutics' score of 0.26 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Disc Medicine	8 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Disc Medicine has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Disc Medicine's return on equity of -37.17% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Disc Medicine	N/A	-37.17%	-33.65%

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aclaris Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	105.53	-$64.92M	-$0.58	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A

Summary

Aclaris Therapeutics beats Disc Medicine on 9 of the 16 factors compared between the two stocks.

Get Aclaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRS vs. The Competition

Export

Metric	Aclaris Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$826.34M	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-10.19	9.02	270.61	25.05
Price / Sales	105.53	1,287.31	657.91	107.93
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	6.95	17.69	11.26	6.43
Net Income	-$64.92M	-$13.25M	$3.45B	$348.10M
7 Day Performance	6.87%	5.04%	3.41%	2.66%
1 Month Performance	5.91%	-2.10%	-0.71%	-0.85%
1 Year Performance	262.58%	61.50%	77.43%	23.96%

Aclaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRS Aclaris Therapeutics	2.1117 of 5 stars	$5.91 flat	$11.50 +94.6%	+262.6%	$826.34M	$7.83M	N/A	100	Earnings Report Gap Up
MBX MBX Biosciences	1.7756 of 5 stars	$64.41 -2.3%	$71.13 +10.4%	N/A	$3.07B	N/A	N/A	N/A	Earnings Report Analyst Forecast
QURE uniQure	3.3674 of 5 stars	$44.06 +1.0%	$65.00 +47.5%	+249.5%	$3.06B	$16.10M	N/A	500
GRAL GRAIL	0.8979 of 5 stars	$70.27 +2.5%	$67.78 -3.5%	+111.7%	$3.02B	$156.12M	N/A	1,360	Earnings Report
CLDX Celldex Therapeutics	2.9085 of 5 stars	$37.69 -1.0%	$54.62 +44.9%	+101.9%	$2.96B	$865K	N/A	150	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRS) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. MBX, QURE, GRAL, CLDX, and IRON

How does Aclaris Therapeutics compare to MBX Biosciences?

Summary

How does Aclaris Therapeutics compare to uniQure?

Summary

How does Aclaris Therapeutics compare to GRAIL?

Summary

How does Aclaris Therapeutics compare to Celldex Therapeutics?

Summary

How does Aclaris Therapeutics compare to Disc Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclaris Therapeutics (ACRS) Competitors

ACRS vs. MBX, QURE, GRAL, CLDX, and IRON

How does Aclaris Therapeutics compare to MBX Biosciences?

Which has preferable valuation & earnings, MBX or ACRS?

Which has more volatility & risk, MBX or ACRS?

Do analysts prefer MBX or ACRS?

Do insiders and institutionals hold more shares of MBX or ACRS?

Is MBX or ACRS more profitable?

Does the media favor MBX or ACRS?

Summary

How does Aclaris Therapeutics compare to uniQure?

Do insiders & institutionals believe in ACRS or QURE?

Which has more risk & volatility, ACRS or QURE?

Do analysts recommend ACRS or QURE?

Does the media favor ACRS or QURE?

Is ACRS or QURE more profitable?

Which has better valuation & earnings, ACRS or QURE?

Summary

How does Aclaris Therapeutics compare to GRAIL?

Does the media refer more to ACRS or GRAL?

Is ACRS or GRAL more profitable?

Which has preferable valuation and earnings, ACRS or GRAL?

Which has more volatility and risk, ACRS or GRAL?

Do analysts recommend ACRS or GRAL?

Do institutionals & insiders believe in ACRS or GRAL?

Summary

How does Aclaris Therapeutics compare to Celldex Therapeutics?

Is ACRS or CLDX more profitable?

Do insiders & institutionals believe in ACRS or CLDX?

Which has better earnings & valuation, ACRS or CLDX?

Which has more risk & volatility, ACRS or CLDX?

Do analysts recommend ACRS or CLDX?

Does the media refer more to ACRS or CLDX?

Summary

How does Aclaris Therapeutics compare to Disc Medicine?

Do analysts recommend ACRS or IRON?

Which has more risk and volatility, ACRS or IRON?

Does the media favor ACRS or IRON?

Is ACRS or IRON more profitable?

Do insiders and institutionals hold more shares of ACRS or IRON?

Which has stronger valuation & earnings, ACRS or IRON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS vs. The Competition

Aclaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools